• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Zemplar (Paricalcitol) Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2011

Summary View

 

WARNINGS

  • Chronic hypercalcemia can lead...
  • Prescription-based doses of vitamin D...
  • Aluminum-containing preparations...
Drug Interactions
  • Specific interaction studies were...
  • ...care should be taken while paricalcitol is...

 

ADVERSE REACTIONS

Other Adverse Reactions Observed...
  • Multiple changes to section
Adverse Events During Post-Marketing Experience
  • ...allergic reactions, such as...have been reported
  • Changes to Overdosage section